Savient Pharmaceuticals Inc., of East Brunswick, N.J., said it will offer $125 million aggregate principal amount of convertible senior notes due 2018. The firm also plans to grant underwriters J.P. Morgan Securities LLC and Lazard Capital Markets LLC an option to purchase up to an additional $18.75 million aggregate principal amount of notes to cover overallotments.